Member Info for Laura2022

Natural hydrogen is an area of strength as potential hydrogen source rocks can be quite clearly fingerprinted in magnetic and gravity data. Given this, Getech is quickly establishing itself in this nascent but potentially vast market, working on several searches during the course of 2024 alongside developing new joint exploration agreements which have the potential to move the Company from being a service provider to be more akin to an explorer with the possibility of greater commercial returns.

And I like the fact after 2023 and 2024 Ceo clearly being cautious and issuing understand able caveats given the fact that some contracts are reliance on the 3rdnparty data as happene in very early 2024

From TU last week

is actively discussing a number of further contracts although there is no guarantee they will be signed within the current financial yea

As I said 2 weeks ago

Strange he has TR1s on BLU DSG PIP but never posts there

Totally agree NK

Afternoon all

Black also taking stake in another similar oil and gas service energy company GTC

Have tried to add more but currently unavailable at 2 pence

I have purchased some today, don't know much about them apart from a brief glance but with annual RR amounting to the market capitalisation it seems a decent bet with a recent TR1 increase also

Annual recurring revenue ("ARR") in FY24 was £2.9m (2023: £2.8m) with the management team continuing to focus on expanding ARR income through a subscription model and aiming to both add new clients and increase the scope of services and value-add provided to existing clients

It's a simple ebb and flow and Fridays usually quiet everywhere

Think if you want EV stuff PODP looks dead cert bounce

BACKGROUND: Promising cancer treatments, such as DDR inhibitors, are often challenged by the heterogeneity of responses in

clinical trials. The present work aimed to build a computational framework to address those challenges.

METHODS: A semi-mechanistic pharmacokinetic-pharmacodynamic model of tumour growth inhibition was developed to

investigate the efficacy of PARP and ATR inhibitors as monotherapies, and in combination. Key features of the DNA damage

response were incorporated into the model to allow the emergence of synthetic lethality, including redundant DNA repair

pathways that may be impaired due to genetic mutations, and due to PARP and ATR inhibition. Model parameters were calibrated

using preclinical in vivo data for PARP inhibitors rucaparib and talazoparib and the ATR inhibitor gartisertib.

RESULTS: The model successfully captured the monotherapy efficacies of rucaparib and talazoparib, as well as the combination

efficacy with gartisertib. The model was evaluated against multiple tumour xenografts with diverse genetic backgrounds and was

able to capture the observed heterogeneity of response profiles.

CONCLUSIONS: By enabling simulation of in vivo tumour growth inhibition with PARP and ATR inhibitors for specific tumour types,

the model provides a rational approach to support the optimisation of dosing regimens to stratified populations.

British Journal of Cancer; https://doi.org/10.1038/s41416-024-02935-w

£24k buy

Panama

I can see that easily

Picked up £2000 more at 10.08p

Delayed buy

Looks 90%+ to be a buy based on the time

Trout

Then sell of you're worried

I have counted the revenues from the publicly declared RNS values!!

It's all there ...

To question /ask KingJ or even the person who posted the TR1 and debull posted their reasons here, rather than being fixated with my views

Filtered

As I said last week , simply filter me if you have a problem

How can I answer or have the evidence for that when the full year ends in June 2025 ?

If you're unhappy

Email Pete S

Or sell

You seem to be selective in what you want to or choose to read

Given the fact that in Q1 2023 and Q1 2024 Jim had to give revised revenues (both no fault of PYC) I'm assuming Pete is being ultra cautious on this update with still 5mths to go

Good to see losses reduced which you haven't mentioned Trout?